clarithromycin / Generic mfg. - LARVOL DELTA

Clinical factors associated with culture conversion in refractory Mycobacterium avium complex-pulmonary disease treated with amikacin liposome inhalation suspension: a meta-analysis (ERS 2026) - "RATIONALE: Amikacin liposome inhalation suspension (ALIS) is an adjunctive therapy for refractory Mycobacterium avium complex-pulmonary disease (MAC-PD). We found four papers and evaluated 135 patients (23 males, 112 females) who were given ALIS therapy for more than 4 months in this meta-analysis. Mycobacterium avium and Mycobacterium intracellulare were identified in 101 and 34 cases, respectively. Cavitary lesions and clarithromycin (CAM) resistance were present in 85 and 43 patients, respectively."

Retrospective data • CNS Disorders • Respiratory Diseases

"Prevalence and Risk Factors of Candidozyma auris Colonization Among Adult ICU Patients in India: Evaluation of a Real-Time PCR Screening Approach". (PubMed, Am J Infect Control) - "C. auris colonization rose eightfold by Day 4; PCR detected more cases than culture, enabling faster infection-control responses. Prior meropenem and azithromycin exposure independently predicted Day-4 colonization, suggesting antimicrobial pressure may contribute, though confounding by illness severity cannot be excluded. These findings support PCR-based surveillance and targeted stewardship to limit transmission."

Journal • Critical care • Infectious Disease • Respiratory Diseases

Phase II Study of Daratumumab, Clarithromycin, Pomalidomide, and Dexamethasone (D-Clapd) in Multiple Myeloma Patients Previously Exposed to Daratumumab (IMS 2026) - P2 | "All patients were prior dara and lenalidomide (len)-exposed, w/ 3/9 (33%) dara-refractory and 7/9 (78%) len-refractory. Seven of 9 (78%) had prior bortezomib exposure and 3/9 (33%) were bortezomib-refractory... D-ClaPd demonstrated moderate efficacy with deep responses observed in previously dara-exposed RRMM pts, w/ ORR 66.7% (≥VGPR 33%; CR 11%), mPFS 12.5 mos and 24-mos OS of 87.5%. The demonstrated efficacy with CD38 retreatment along with a manageable toxicity profile supports D-ClaPd as a tolerable and effective treatment option in this population."

Clinical • IO biomarker • P2 data • Atrial Fibrillation • Cardiovascular • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Pneumonia • Retinal Disorders • CD38 • IL6

Pharmacokinetic and safety interactions between aildenafil and clarithromycin, cimetidine, or rifampin in healthy subjects. (PubMed, Br J Clin Pharmacol) - "Coadministration of aildenafil with the strong CYP3A4 inhibitor clarithromycin increased aildenafil AUC0-∞ by 2.58-fold and Cmax by 1.67-fold; therefore, dose adjustment should be guided by clinical response and tolerability. In contrast, coadministration with the strong CYP3A4 inducer rifampin is not recommended."

Journal • PK/PD data

Deep Mycobacterium marinum Infection of the Digit Presenting Without Cutaneous Lesions: A Case Report. (PubMed, Cureus) - "Antimycobacterial therapy with rifampicin and clarithromycin was given for six months. The patient regained PIPJ flexion up to 110° and returned to work pain-free. This case highlights that M. marinum should be considered in chronic monoarticular digital swelling with relevant aquatic exposure, even when the characteristic skin lesion is absent, and illustrates the value of tissue biopsy with molecular confirmation and combined surgical and medical management for deep disease."

Journal • Infectious Disease • Inflammation • Nontuberculous Mycobacterial Disease • Pain • Respiratory Diseases

DISCORDANT CLARITHROMYCIN SUSCEPTIBILITY ACROSS TWO MYCOBACTERIUM AVIUM COLONY MORPHOTYPES FROM A SINGLE CULTURE (CHEST 2026) - No abstract available

Discordant • Bronchiectasis • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Reconsidering First-Line Therapy for Clarithromycin-Resistant Helicobacter pylori in Korea: The Role of Bismuth-Augmented Triple Therapy. (PubMed, Gut Liver) - No abstract available

Journal • Infectious Disease

Current Practice in the Diagnosis and Management of Mycoplasma pneumoniae Infections: A Survey of Korean Physicians in 2024. (PubMed, J Korean Med Sci) - "This study reveals diverse practices and a need for standardized guidelines in managing M. pneumoniae infections, particularly in the context of rising MRMP prevalence. Clearer recommendations on diagnostic testing, antibiotic selection, and corticosteroid use are crucial to optimize patient care and mitigate the spread of resistance."

Journal • Infectious Disease • Pediatrics • Pneumonia • Respiratory Diseases

Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial. (PubMed, Gut Liver) - "Further large-scale studies are needed to validate these results. Registered retrospectively with the Clinical Research Information Service (CRIS; KCT0012265)."

Clinical • Journal • Infectious Disease

Randomized controlled trial comparing 7-day fexuprazan-based and 14-day rabeprazole-based triple therapies for Helicobacter pylori eradication. (PubMed, Medicine (Baltimore)) - "Seven-day fexuprazan-based triple therapy demonstrated eradication efficacy comparable with that of 14-day rabeprazole-based therapy in treatment-naïve Korean patients with H. pylori infection. The fexuprazan-based regimen showed a similar safety profile and comparable incidence of adverse events with that of the rabeprazole-based regimen."

Clinical • Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Sex Differences in Helicobacter pylori Antimicrobial Resistance among 890 Subjects over 20 Years in a Korean Tertiary Hospital. (PubMed, Gut Liver) - P=N/A | "Minimum inhibitory concentration tests were performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin using the agar dilution method. These findings highlight the importance of considering sex differences when interpreting antimicrobial resistance patterns and selecting eradication strategies. (ClinicalTrials.gov identifier NCT05247112)."

Journal • Infectious Disease

HED-2T: Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori (clinicaltrials.gov) - P=N/A | N=250 | Not yet recruiting | Sponsor: Clinique Bizet

New trial • Infectious Disease

Detection of Helicobacter pylori and Clarithromycin Resistance by Multiplex PCR: Assay Validation and Implementation Strategies (IDWeek 2026) - No abstract available

Infectious Disease

Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Ain Shams University | Trial completion date: Nov 2025 ➔ Nov 2026

Trial completion date • Infectious Disease

Antibacterial consumption in four paediatric inpatient facilities in Sri Lanka in 2023: a cross-sectional descriptive study. (PubMed, BMJ Open) - "High use of broad-spectrum and Watch-group antibacterials was observed across the four paediatric inpatient facilities. The findings highlight targets for antibacterial stewardship programmes and demonstrate the feasibility of ABC surveillance in Sri Lanka."

Journal • Pediatrics

Zebrafish larvae swim bladder serves as a model to study Mycobacterium abscessus infection kinetics, host-pathogen interactions and drug efficacy. (PubMed, Mycobacteria) - "To study drug efficacy in this model, zebrafish larvae were infected into the swim bladder with M. abscessus:eGFP, treated with clarithromycin or omadacycline by immersion and CFU counts were determined at 2- and 4-day post-treatment. Overall, this study established the first zebrafish: M. abscessus swim bladder infection model to study localized NTM infection, host-pathogen interactions, and drug efficacy studies."

Journal • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases • TNFA

A case of pulmonary Mycobacterium kansasii presenting with an atypical extensive consolidation involving the entire right lower lobe. (PubMed, Respir Med Case Rep) - "Treatment with rifampicin, ethambutol, and clarithromycin was initiated, resulting in improvement of symptoms and radiography findings...kansasii infection typically presents with thin-walled cavities in the upper lung lobes. We report a rare case of atypical radiological findings characterized by extensive consolidation in the right lower lobe."

Journal • Infectious Disease

Bismuth Quadruple Therapy Versus Modified Bismuth Therapy for Helicobacter Pylori (clinicaltrials.gov) - P3 | N=200 | Completed | Sponsor: Reham Abdelkader Elkhouly

New P3 trial • Infectious Disease

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Tanta University | N=66 ➔ 132

Enrollment change • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Single-cell Raman spectroscopy combined with deep learning for antimicrobial resistance detection in Mycobacterium abscessus. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "Cells were incubated in medium containing 50% D2O under exposure to clarithromycin (CLA) or linezolid (LZD), and metabolic activity was quantified via the CD ratio...This study establishes a rapid, label-free platform for detecting antimicrobial resistance in M. abscessus based on metabolic phenotyping. The presented approach could be adapted to streamline resistance profiling of clinical isolates, aiding in timely therapeutic decision-making."

Journal • Nontuberculous Mycobacterial Disease

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (clinicaltrials.gov) - P3 | N=88 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2026 ➔ Feb 2027 | Trial primary completion date: Apr 2026 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease

The Divergent Metabolomic Landscape of COVID-19 and Community-Acquired Pneumonia. (PubMed, Crit Care Explor) - P2, P3 | "Extensive divergence was observed in the metabolomic landscape of patients with COVID-19 or CAP, underscoring the disease-specific metabolic adaptations and providing potential targets for diagnostic and therapeutic development."

Clinical • Journal • Observational data • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Evaluation of Posttreatment Eradication Testing Following Helicobacter pylori Therapy. (PubMed, Perm J) - "Eradication testing was not completed in nearly half (39%) of this cohort, and clarithromycin triple therapy continued to be frequently utilized despite recent guideline changes, suggesting an opportunity for practitioner education and improved patient outcomes."

Journal • Allergy • Immunology • Infectious Disease

Clinical characteristics of Tropheryma whipplei pneumonia: A retrospective analysis based on five cases. (PubMed, IDCases) - "Four patients received ceftriaxone combined with doxycycline or compound sulfamethoxazole tablets, while one treated empirically with cefotetan. Early diagnosis requires relies on mNGS, and treatment mainly bases on the third-generation cephalosporin combined with tetracycline or sulfonamides. Sequential therapy with sulfamethoxazole and clarithromycin is effective, and close follow-up needs to determine the total course of treatment."

Journal • Retrospective data • Cough • Hematological Disorders • Infectious Disease • Pneumonia • Respiratory Diseases • CRP

Molecular characterisation and mutational analysis of antimicrobial resistance genes in Helicobacter pylori isolates in Erbil, Iraq. (PubMed, Mutat Res) - "This study provides the first molecular surveillance data on antimicrobial resistance in Helicobacter pylori in northern Iraq, offering valuable regional evidence to guide local eradication strategies. The relatively high amoxicillin resistance, together with the elevated resistance to metronidazole, levofloxacin, and clarithromycin, underscores the need for susceptibility-guided therapy and continuous local antimicrobial resistance surveillance."

Biomarker • Journal • Dyspepsia • Infectious Disease